Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
IDF carried out mission to locate former hostage Avera Mengistu a day before Oct. 7 - 220-year-old who threatened German train attack remanded in custody
- 36 Useful Home Espresso Machines
- 4Tech Devices 2023: The Most blazing Arrivals of the Year
- 5Get To Be familiar with The Historical backdrop Of Western Medication
- 6 Web-based Staple Help You Can Trust
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- What causes RFK Jr.’s strained and shaky voice? A neurologist explains this little-known disorder
- Extraordinary Guinness World Records That Will Astound You
- Melodic Event: A Survey of \Energies and Exhibitions Assessed\ Live concert
- Pick Your Number one breakfast food
- Humpback whale freed by rescuers in Baltic Sea has become stranded again
- 7 Countries Where You Can Buy a Home for Under $100,000
- What's A Decent FICO rating?
